Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID	DTD0278 Transporter Info
Gene Name	SLC31A1
Transporter Name	High affinity copper uptake protein 1
Gene ID	1317
UniProt ID	O15431

Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)
Herbicide
DT Modulation1	SLC31A1 gene results in decreased susceptibility to Paraquat		[75]
Regulation Mechanism			Transcription Factor Info
Approved Drug
Decitabine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Decitabine increases the expression of SLC31A1		[1]
Isotretinoin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Isotretinoin inhibits the expression of SLC31A1		[2]
Paclitaxel	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Paclitaxel increases the expression of SLC31A1		[3]
Celecoxib	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Celecoxib inhibits the expression of SLC31A1		[4]
Acetaminophen	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Acetaminophen inhibits the expression of SLC31A1		[5]
Penicillamine	6 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Penicillamine increases the expression of SLC31A1		[6]
Tretinoin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Tretinoin increases the expression of SLC31A1		[7]
Zinc Acetate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Zinc Acetate increases the expression of SLC31A1		[8]
Cupric chloride	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Cupric chloride inhibits the expression of SLC31A1		[9]
Ivermectin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Ivermectin inhibits the expression of SLC31A1		[10]
Copper	35 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Copper inhibits the expression of SLC31A1		[11]
Estradiol	4 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Estradiol induces the activity of SLC31A1		[11]
Cisplatin	41 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Cisplatin inhibits the activity of SLC31A1		[12]
Copper Sulfate	6 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Cupric sulfate inhibits the activity of SLC31A1		[12]
Drug Marketed but not Approved by US FDA
Silver Nitrate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Silver Nitrate increases the expression of SLC31A1		[8]
Drug in Phase 3 Trial
Resveratrol	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Resveratrol increases the expression of SLC31A1		[15]
Tetrathiomolybdate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Tetrathiomolybdate increases the expression of SLC31A1		[6]
Epigallocatechin gallate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Epigallocatechin gallate increases the expression of SLC31A1		[28]
Drug in Phase 2 Trial
Bisphenol A	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Bisphenol A increases the expression of SLC31A1		[15]
Genistein	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Genistein increases the expression of SLC31A1		[27]
Drug in Phase 1 Trial
Trichostatin A	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Trichostatin A affects the expression of SLC31A1		[22]
Drug in Preclinical Test
SC-58236	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	SC-58236 inhibits the expression of SLC31A1		[4]
Investigative Drug
Coumestrol	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Coumestrol increases the expression of SLC31A1		[14]
Metribolone	4 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Metribolone increases the expression of SLC31A1		[19]
Phenylmercuric Acetate	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Phenylmercuric Acetate increases the expression of SLC31A1		[21]
Milchsaure	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Milchsaure inhibits the expression of SLC31A1		[24]
Patented Pharmaceutical Agent
GSK-J4	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	GSK-J4 increases the expression of SLC31A1		[23]
Natural Product
Coal Ash	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Coal Ash inhibits the expression of SLC31A1		[13]
Tobacco Smoke Pollution	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Tobacco Smoke Pollution increases the expression of SLC31A1		[25]
Environmental toxicant
Polychlorinated dibenzodioxin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Polychlorinated dibenzodioxin increases the expression of SLC31A1		[20]
Mycotoxins
Aflatoxin B1	3 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Aflatoxin B1 inhibits the expression of SLC31A1		[16]
DT Modulation2	Aflatoxin B1 affects the expression of SLC31A1 protein		[33]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Aflatoxin B1 results in decreased methylation of SLC31A1 gene		[34]
Regulation Mechanism			Transcription Factor Info
Zearalenone	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Zearalenone results in increased expression of SLC31A1 mRNA		[15]
Regulation Mechanism			Transcription Factor Info
Acute Toxic Substance
Formaldehyde	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Formaldehyde inhibits the expression of SLC31A1		[17]
Paraquat	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Paraquat increases the expression of SLC31A1		[26]
Carcinogen
Ethyl Methanesulfonate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Ethyl Methanesulfonate inhibits the expression of SLC31A1		[17]
Benzo(a)pyrene	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Benzo(a)pyrene inhibits the expression of SLC31A1		[29]
Arsenic	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	sodium arsenite results in increased abundance of Arsenic which results in increased expression of SLC31A1 mRNA		[36]
Regulation Mechanism			Transcription Factor Info
Cadmium	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Cadmium Chloride results in increased abundance of Cadmium which results in decreased expression of SLC31A1 mRNA		[42]
Regulation Mechanism			Transcription Factor Info
Chemical Compound
DT Modulation1	Celecoxib results in decreased expression of SLC31A1 protein which results in decreased import of and results in decreased susceptibility to Cisplatin		[4]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	Cisplatin promotes the reaction Penicillamine results in increased expression of SLC31A1 mRNA		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Penicillamine promotes the reaction Cisplatin results in increased expression of SLC31A1 mRNA		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Penicillamine results in increased expression of SLC31A1 mRNA which results in decreased susceptibility to Oxaliplatin		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	Penicillamine results in increased expression of SLC31A1 mRNA which results in increased susceptibility to Carboplatin		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation5	Penicillamine results in increased expression of SLC31A1 mRNA which results in increased susceptibility to Cisplatin		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	bathocuproine sulfonate results in decreased abundance of Copper which results in increased expression of SLC31A1 mRNA		[37]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Buthionine Sulfoximine inhibits the reaction SLC31A1 protein results in increased import of Copper		[41]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Buthionine Sulfoximine results in decreased abundance of Glutathione inhibits the reaction SLC31A1 protein results in increased import of Copper		[41]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	Chlorpromazine inhibits the reaction Copper affects the localization of SLC31A1 protein		[45]
Regulation Mechanism			Transcription Factor Info
DT Modulation5	Cisplatin inhibits the reaction SLC31A1 protein results in increased import of Copper		[8]
Regulation Mechanism			Transcription Factor Info
DT Modulation6	CLDN3 protein results in increased expression of SLC31A1 protein which results in increased import of and results in increased abundance of Copper		[47]
Regulation Mechanism			Transcription Factor Info
DT Modulation7	CLDN4 protein results in increased expression of SLC31A1 protein which results in increased import of and results in increased abundance of Copper		[47]
Regulation Mechanism			Transcription Factor Info
DT Modulation8	Copper affects the localization of SLC31A1 protein		[45]
Regulation Mechanism			Transcription Factor Info
DT Modulation9	Copper deficiency promotes the reaction SP1 protein results in increased expression of SLC31A1 mRNA		[57]
Regulation Mechanism			Transcription Factor Info
DT Modulation10	Copper deficiency results in increased expression of SLC31A1 mRNA		[37]
Regulation Mechanism			Transcription Factor Info
DT Modulation11	Copper deficiency results in increased expression of SLC31A1 protein		[58]
Regulation Mechanism			Transcription Factor Info
DT Modulation12	Copper inhibits the reaction SP1 protein results in increased expression of SLC31A1 mRNA		[37]
Regulation Mechanism			Transcription Factor Info
DT Modulation13	Copper results in decreased expression of and affects the localization of SLC31A1 protein		[59]
Regulation Mechanism			Transcription Factor Info
DT Modulation14	Copper results in decreased expression of SLC31A1 mRNA which results in decreased uptake of Copper		[37]
Regulation Mechanism			Transcription Factor Info
DT Modulation15	Copper results in increased degradation of and affects the localization of SLC31A1 protein		[60]
Regulation Mechanism			Transcription Factor Info
DT Modulation16	Copper results in increased degradation of SLC31A1 protein		[45]
Regulation Mechanism			Transcription Factor Info
DT Modulation17	Copper results in increased expression of SLC31A1 protein		[61]
Regulation Mechanism			Transcription Factor Info
DT Modulation18	Estradiol inhibits the reaction Copper results in decreased expression of SLC31A1 protein		[11]
Regulation Mechanism			Transcription Factor Info
DT Modulation19	Estradiol promotes the reaction Copper affects the expression of SLC31A1 mRNA		[11]
Regulation Mechanism			Transcription Factor Info
DT Modulation20	glutathione diethyl ester inhibits the reaction Buthionine Sulfoximine inhibits the reaction SLC31A1 protein results in increased import of Copper		[41]
Regulation Mechanism			Transcription Factor Info
DT Modulation21	ITGAV protein results in decreased expression of SLC31A1 protein which results in decreased abundance of Copper		[49]
Regulation Mechanism			Transcription Factor Info
DT Modulation22	methyl-beta-cyclodextrin inhibits the reaction Copper affects the localization of SLC31A1 protein		[45]
Regulation Mechanism			Transcription Factor Info
DT Modulation23	Metribolone results in increased expression of SLC31A1 protein which results in increased import of Copper		[19]
Regulation Mechanism			Transcription Factor Info
DT Modulation24	NSC 689534 binds to Copper which results in increased expression of SLC31A1 mRNA		[62]
Regulation Mechanism			Transcription Factor Info
DT Modulation25	SLC11A2 protein co-treated with SLC31A1 protein affects the uptake of Copper		[63]
Regulation Mechanism			Transcription Factor Info
DT Modulation26	SLC31A1 mutant form results in decreased uptake of Copper		[64]
Regulation Mechanism			Transcription Factor Info
DT Modulation27	SLC31A1 protein affects the uptake of Copper		[65]
Regulation Mechanism			Transcription Factor Info
DT Modulation28	SLC31A1 protein mutant form results in decreased susceptibility to Copper		[52]
Regulation Mechanism			Transcription Factor Info
DT Modulation29	SLC31A1 protein mutant form results in decreased transport of Copper		[52]
Regulation Mechanism			Transcription Factor Info
DT Modulation30	SLC31A1 protein mutant form results in increased uptake of Copper		[64]
Regulation Mechanism			Transcription Factor Info
DT Modulation31	SLC31A1 protein results in increased import of Copper		[41]
Regulation Mechanism			Transcription Factor Info
DT Modulation32	SLC31A1 protein results in increased susceptibility to cupric chloride results in increased abundance of Copper		[66]
Regulation Mechanism			Transcription Factor Info
DT Modulation33	SLC31A1 protein results in increased transport of Copper		[67]
Regulation Mechanism			Transcription Factor Info
DT Modulation34	SLC31A1 protein results in increased uptake of Copper		[68]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	Estradiol inhibits the reaction Copper results in decreased expression of SLC31A1 protein		[11]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Estradiol promotes the reaction Copper affects the expression of SLC31A1 mRNA		[11]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Estradiol results in increased expression of SLC31A1 mRNA		[11]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide results in decreased expression of SLC31A1 protein which results in decreased import of and results in decreased susceptibility to Cisplatin		[4]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Amiloride inhibits the reaction Cisplatin results in increased degradation of SLC31A1 protein		[35]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal inhibits the reaction Cisplatin results in increased degradation of SLC31A1 protein		[35]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction Cisplatin results in increased degradation of SLC31A1 protein		[35]
Regulation Mechanism			Transcription Factor Info
DT Modulation5	Bortezomib inhibits the reaction Cisplatin results in decreased expression of SLC31A1 protein		[39]
Regulation Mechanism			Transcription Factor Info
DT Modulation6	Bortezomib inhibits the reaction Cisplatin results in decreased expression of SLC31A1 protein which results in increased uptake of Cisplatin		[39]
Regulation Mechanism			Transcription Factor Info
DT Modulation7	Celecoxib results in decreased expression of SLC31A1 protein which results in decreased import of and results in decreased susceptibility to Cisplatin		[4]
Regulation Mechanism			Transcription Factor Info
DT Modulation8	Cisplatin inhibits the reaction SLC31A1 protein results in increased import of Copper		[8]
Regulation Mechanism			Transcription Factor Info
DT Modulation9	Cisplatin promotes the reaction Penicillamine results in increased expression of SLC31A1 mRNA		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation10	Cisplatin promotes the reaction SLC31A1 protein binds to SLC31A1 protein		[46]
Regulation Mechanism			Transcription Factor Info
DT Modulation11	Cisplatin results in decreased expression of SLC31A1 protein		[39]
Regulation Mechanism			Transcription Factor Info
DT Modulation12	Cisplatin results in increased degradation of SLC31A1 protein		[35]
Regulation Mechanism			Transcription Factor Info
DT Modulation13	Cisplatin results in increased expression of SLC31A1 mRNA		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation14	Cisplatin results in increased expression of SLC31A1 protein		[8]
Regulation Mechanism			Transcription Factor Info
DT Modulation15	Cisplatin results in increased expression of SP1 protein which results in increased expression of SLC31A1 mRNA		[8]
Regulation Mechanism			Transcription Factor Info
DT Modulation16	CLDN3 protein results in increased expression of SLC31A1 protein which results in increased import of Cisplatin		[47]
Regulation Mechanism			Transcription Factor Info
DT Modulation17	CLDN4 protein results in increased expression of SLC31A1 protein which results in increased import of Cisplatin		[47]
Regulation Mechanism			Transcription Factor Info
DT Modulation18	Copper Sulfate inhibits the reaction Cisplatin results in increased expression of SLC31A1 mRNA		[8]
Regulation Mechanism			Transcription Factor Info
DT Modulation19	Copper Sulfate inhibits the reaction SLC31A1 protein results in increased import of Cisplatin		[8]
Regulation Mechanism			Transcription Factor Info
DT Modulation20	Cytochalasin D inhibits the reaction Cisplatin results in increased degradation of SLC31A1 protein		[35]
Regulation Mechanism			Transcription Factor Info
DT Modulation21	epigallocatechin gallate inhibits the reaction Cisplatin results in increased degradation of SLC31A1 protein		[48]
Regulation Mechanism			Transcription Factor Info
DT Modulation22	ITGAV protein results in decreased expression of SLC31A1 protein which results in decreased abundance of Cisplatin		[49]
Regulation Mechanism			Transcription Factor Info
DT Modulation23	lactacystin inhibits the reaction Cisplatin results in increased degradation of SLC31A1 protein		[35]
Regulation Mechanism			Transcription Factor Info
DT Modulation24	Penicillamine promotes the reaction Cisplatin results in increased expression of SLC31A1 mRNA		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation25	Penicillamine results in increased expression of SLC31A1 mRNA which results in increased susceptibility to Cisplatin		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation26	SLC31A1 mRNA affects the susceptibility to Cisplatin		[50]
Regulation Mechanism			Transcription Factor Info
DT Modulation27	SLC31A1 protein affects the susceptibility to Cisplatin		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation28	SLC31A1 protein affects the uptake of Cisplatin		[51]
Regulation Mechanism			Transcription Factor Info
DT Modulation29	SLC31A1 protein affects the uptake of Cisplatin which affects the abundance of cisplatin-DNA adduct		[28]
Regulation Mechanism			Transcription Factor Info
DT Modulation30	SLC31A1 protein mutant form results in increased susceptibility to Cisplatin		[52]
Regulation Mechanism			Transcription Factor Info
DT Modulation31	SLC31A1 protein mutant form results in increased uptake of Cisplatin		[52]
Regulation Mechanism			Transcription Factor Info
DT Modulation32	SLC31A1 protein results in decreased susceptibility to Cisplatin		[9]
Regulation Mechanism			Transcription Factor Info
DT Modulation33	SLC31A1 protein results in increased import of and results in increased susceptibility to Cisplatin		[53]
Regulation Mechanism			Transcription Factor Info
DT Modulation34	SLC31A1 protein results in increased import of Cisplatin		[8]
Regulation Mechanism			Transcription Factor Info
DT Modulation35	SLC31A1 protein results in increased susceptibility to Cisplatin		[44]
Regulation Mechanism			Transcription Factor Info
DT Modulation36	SLC31A1 protein results in increased transport of Cisplatin		[46]
Regulation Mechanism			Transcription Factor Info
DT Modulation37	SLC31A1 protein results in increased uptake of and results in increased susceptibility to Cisplatin		[54]
Regulation Mechanism			Transcription Factor Info
DT Modulation38	SLC31A1 protein results in increased uptake of Cisplatin		[44]
Regulation Mechanism			Transcription Factor Info
DT Modulation39	tetrathiomolybdate results in increased expression of SLC31A1 mRNA which results in increased susceptibility to Cisplatin		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation40	Trientine results in increased expression of SLC31A1 mRNA which results in increased susceptibility to Cisplatin		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	Copper Sulfate inhibits the reaction Cisplatin results in increased expression of SLC31A1 mRNA		[8]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Copper Sulfate inhibits the reaction SLC31A1 protein results in increased import of Cisplatin		[8]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Copper Sulfate inhibits the reaction SP1 protein binds to SLC31A1 promoter		[57]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	Copper Sulfate results in decreased expression of SLC31A1 mRNA		[69]
Regulation Mechanism			Transcription Factor Info
DT Modulation5	Copper Sulfate results in decreased expression of SP1 mRNA which results in decreased expression of SLC31A1 mRNA		[57]
Regulation Mechanism			Transcription Factor Info
Cupric oxide	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Cupric oxide increases the expression of SLC31A1		[18]
DT Modulation1	AR protein promotes the reaction Metribolone results in increased expression of SLC31A1 mRNA		[19]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	AR protein promotes the reaction Metribolone results in increased expression of SLC31A1 protein		[19]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Metribolone results in increased expression of SLC31A1 protein which results in increased import of Copper		[19]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC31A1 mRNA		[31]
Regulation Mechanism			Transcription Factor Info
DT Modulation1	Benzo(a)pyrene results in decreased methylation of SLC31A1 5' UTR		[38]
Regulation Mechanism			Transcription Factor Info
3-iodothyronamine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	SLC31A1 mRNA affects the uptake of 3-iodothyronamine		[30]
Regulation Mechanism			Transcription Factor Info
4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide results in decreased expression of SLC31A1 protein		[4]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide results in decreased expression of SLC31A1 protein which results in decreased import of and results in decreased susceptibility to Cisplatin		[4]
Regulation Mechanism			Transcription Factor Info
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC31A1 mRNA		[31]
Regulation Mechanism			Transcription Factor Info
abrine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	abrine results in decreased expression of SLC31A1 mRNA		[32]
Regulation Mechanism			Transcription Factor Info
Amiloride	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Amiloride inhibits the reaction Cisplatin results in increased degradation of SLC31A1 protein		[35]
Regulation Mechanism			Transcription Factor Info
bathocuproine sulfonate	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	bathocuproine sulfonate promotes the reaction SP1 protein results in increased expression of SLC31A1 mRNA		[37]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	bathocuproine sulfonate results in decreased abundance of Copper which results in increased expression of SLC31A1 mRNA		[37]
Regulation Mechanism			Transcription Factor Info
benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal inhibits the reaction Cisplatin results in increased degradation of SLC31A1 protein		[35]
Regulation Mechanism			Transcription Factor Info
benzyloxycarbonylleucyl-leucyl-leucine aldehyde	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction Cisplatin results in increased degradation of SLC31A1 protein		[35]
Regulation Mechanism			Transcription Factor Info
bisphenol A	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	bisphenol A results in increased expression of SLC31A1 mRNA		[15]
Regulation Mechanism			Transcription Factor Info
Bortezomib	4 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Bortezomib inhibits the reaction Cisplatin results in decreased expression of SLC31A1 protein		[39]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Bortezomib inhibits the reaction Cisplatin results in decreased expression of SLC31A1 protein which results in increased uptake of Cisplatin		[39]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Bortezomib results in decreased degradation of SLC31A1 protein		[40]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	Bortezomib results in decreased degradation of SLC31A1 protein which results in increased uptake of Platinum		[40]
Regulation Mechanism			Transcription Factor Info
Buthionine Sulfoximine	3 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Buthionine Sulfoximine inhibits the reaction SLC31A1 protein results in increased import of Copper		[41]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Buthionine Sulfoximine results in decreased abundance of Glutathione inhibits the reaction SLC31A1 protein results in increased import of Copper		[41]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	glutathione diethyl ester inhibits the reaction Buthionine Sulfoximine inhibits the reaction SLC31A1 protein results in increased import of Copper		[41]
Regulation Mechanism			Transcription Factor Info
cadmium acetate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	cadmium acetate results in decreased expression of SLC31A1 mRNA		[8]
Regulation Mechanism			Transcription Factor Info
Cadmium Chloride	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Cadmium Chloride results in increased abundance of Cadmium which results in decreased expression of SLC31A1 mRNA		[42]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Cadmium Chloride results in increased expression of SLC31A1 mRNA		[43]
Regulation Mechanism			Transcription Factor Info
Carboplatin	5 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Penicillamine results in increased expression of SLC31A1 mRNA which results in increased susceptibility to Carboplatin		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	SLC31A1 protein results in increased susceptibility to Carboplatin		[44]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	SLC31A1 protein results in increased uptake of Carboplatin		[44]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	tetrathiomolybdate results in increased expression of SLC31A1 mRNA which results in increased susceptibility to Carboplatin		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation5	Trientine results in increased expression of SLC31A1 mRNA which results in increased susceptibility to Carboplatin		[6]
Regulation Mechanism			Transcription Factor Info
Chlorpromazine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Chlorpromazine inhibits the reaction Copper affects the localization of SLC31A1 protein		[45]
Regulation Mechanism			Transcription Factor Info
cobaltous chloride	3 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	cobaltous chloride results in increased expression of SLC31A1 mRNA		[55]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	SLC31A1 mutant form inhibits the reaction cobaltous chloride results in decreased expression of CDH1 protein		[56]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	SLC31A1 mutant form inhibits the reaction cobaltous chloride results in increased expression of VIM mRNA		[56]
Regulation Mechanism			Transcription Factor Info
cupric chloride	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	cupric chloride results in decreased expression of SLC31A1 protein		[9]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	SLC31A1 protein results in increased susceptibility to cupric chloride results in increased abundance of Copper		[66]
Regulation Mechanism			Transcription Factor Info
cupric oxide	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	cupric oxide analog results in increased expression of SLC31A1 mRNA		[18]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	cupric oxide analog results in increased expression of SLC31A1 protein		[18]
Regulation Mechanism			Transcription Factor Info
Cytochalasin D	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Cytochalasin D inhibits the reaction Cisplatin results in increased degradation of SLC31A1 protein		[35]
Regulation Mechanism			Transcription Factor Info
Diazinon	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Diazinon results in increased methylation of SLC31A1 gene		[70]
Regulation Mechanism			Transcription Factor Info
di-n-butylphosphoric acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	di-n-butylphosphoric acid affects the expression of SLC31A1 mRNA		[71]
Regulation Mechanism			Transcription Factor Info
dorsomorphin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC31A1 mRNA		[31]
Regulation Mechanism			Transcription Factor Info
epigallocatechin gallate	4 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	epigallocatechin gallate inhibits the reaction Cisplatin results in increased degradation of SLC31A1 protein		[48]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	epigallocatechin gallate results in increased expression of and affects the localization of SLC31A1 protein		[28]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	epigallocatechin gallate results in increased expression of SLC31A1 mRNA		[48]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	epigallocatechin gallate results in increased expression of SLC31A1 protein		[48]
Regulation Mechanism			Transcription Factor Info
Glutathione	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Buthionine Sulfoximine results in decreased abundance of Glutathione inhibits the reaction SLC31A1 protein results in increased import of Copper		[41]
Regulation Mechanism			Transcription Factor Info
glutathione diethyl ester	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	glutathione diethyl ester inhibits the reaction Buthionine Sulfoximine inhibits the reaction SLC31A1 protein results in increased import of Copper		[41]
Regulation Mechanism			Transcription Factor Info
lactacystin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	lactacystin inhibits the reaction Cisplatin results in increased degradation of SLC31A1 protein		[35]
Regulation Mechanism			Transcription Factor Info
Lactic Acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Lactic Acid results in decreased expression of SLC31A1 mRNA		[24]
Regulation Mechanism			Transcription Factor Info
Lamivudine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Zidovudine co-treated with Lamivudine results in increased expression of SLC31A1 mRNA		[72]
Regulation Mechanism			Transcription Factor Info
methyl-beta-cyclodextrin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	methyl-beta-cyclodextrin inhibits the reaction Copper affects the localization of SLC31A1 protein		[45]
Regulation Mechanism			Transcription Factor Info
methylmercuric chloride	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	methylmercuric chloride results in increased expression of SLC31A1 mRNA		[73]
Regulation Mechanism			Transcription Factor Info
Methyl Methanesulfonate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Methyl Methanesulfonate results in decreased expression of SLC31A1 mRNA		[17]
Regulation Mechanism			Transcription Factor Info
NSC 689534	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	NSC 689534 binds to Copper which results in increased expression of SLC31A1 mRNA		[62]
Regulation Mechanism			Transcription Factor Info
NSC73306	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	NSC73306 results in decreased expression of SLC31A1 protein		[9]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	SLC31A1 protein results in increased uptake of NSC73306		[9]
Regulation Mechanism			Transcription Factor Info
o,p'-DDT	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	o,p'-DDT results in increased expression of SLC31A1 mRNA		[15]
Regulation Mechanism			Transcription Factor Info
Oxaliplatin	6 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Penicillamine results in increased expression of SLC31A1 mRNA which results in decreased susceptibility to Oxaliplatin		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	SLC31A1 protein affects the susceptibility to Oxaliplatin		[74]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	SLC31A1 protein results in increased susceptibility to Oxaliplatin		[44]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	SLC31A1 protein results in increased uptake of Oxaliplatin		[44]
Regulation Mechanism			Transcription Factor Info
DT Modulation5	tetrathiomolybdate results in increased expression of SLC31A1 mRNA which results in decreased susceptibility to Oxaliplatin		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation6	Trientine results in increased expression of SLC31A1 mRNA which results in decreased susceptibility to Oxaliplatin		[6]
Regulation Mechanism			Transcription Factor Info
Oxygen	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	HIF1A mRNA promotes the reaction Oxygen deficiency results in increased expression of SLC31A1 mRNA		[55]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Oxygen deficiency results in increased expression of SLC31A1 mRNA		[55]
Regulation Mechanism			Transcription Factor Info
Platinum	4 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Bortezomib results in decreased degradation of SLC31A1 protein which results in increased uptake of Platinum		[40]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	SLC31A1 affects the susceptibility to Platinum		[76]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	SLC31A1 protein results in increased uptake of Platinum		[77]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	Trientine promotes the reaction SLC31A1 protein results in increased uptake of Platinum		[77]
Regulation Mechanism			Transcription Factor Info
Sirolimus	4 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Sirolimus affects the reaction SLC31A1 protein affects the expression of BAX protein		[78]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Sirolimus affects the reaction SLC31A1 protein affects the expression of BCL2 protein		[78]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Sirolimus affects the reaction SLC31A1 protein affects the phosphorylation of AKT1 protein		[78]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	Sirolimus affects the reaction SLC31A1 protein affects the phosphorylation of MTOR protein		[78]
Regulation Mechanism			Transcription Factor Info
sodium arsenite	2 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	sodium arsenite results in increased abundance of Arsenic which results in increased expression of SLC31A1 mRNA		[36]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	sodium arsenite results in increased expression of SLC31A1 mRNA		[79]
Regulation Mechanism			Transcription Factor Info
Tetrachlorodibenzodioxin	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Tetrachlorodibenzodioxin results in increased expression of SLC31A1 mRNA		[20]
Regulation Mechanism			Transcription Factor Info
tetrathiomolybdate	6 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	tetrathiomolybdate promotes the reaction SP1 protein binds to SLC31A1 promoter		[57]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	tetrathiomolybdate results in decreased expression of SLC31A1 protein		[78]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	tetrathiomolybdate results in increased expression of SLC31A1 mRNA		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	tetrathiomolybdate results in increased expression of SLC31A1 mRNA which results in decreased susceptibility to Oxaliplatin		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation5	tetrathiomolybdate results in increased expression of SLC31A1 mRNA which results in increased susceptibility to Carboplatin		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation6	tetrathiomolybdate results in increased expression of SLC31A1 mRNA which results in increased susceptibility to Cisplatin		[6]
Regulation Mechanism			Transcription Factor Info
trichostatin A	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	trichostatin A affects the expression of SLC31A1 mRNA		[22]
Regulation Mechanism			Transcription Factor Info
Trientine	6 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Trientine promotes the reaction SLC31A1 protein results in increased uptake of Platinum		[77]
Regulation Mechanism			Transcription Factor Info
DT Modulation2	Trientine results in increased expression of SLC31A1 mRNA		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation3	Trientine results in increased expression of SLC31A1 mRNA which results in decreased susceptibility to Oxaliplatin		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation4	Trientine results in increased expression of SLC31A1 mRNA which results in increased susceptibility to Carboplatin		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation5	Trientine results in increased expression of SLC31A1 mRNA which results in increased susceptibility to Cisplatin		[6]
Regulation Mechanism			Transcription Factor Info
DT Modulation6	Trientine results in increased expression of SLC31A1 protein		[6]
Regulation Mechanism			Transcription Factor Info
triphenyl phosphate	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	triphenyl phosphate affects the expression of SLC31A1 mRNA		[71]
Regulation Mechanism			Transcription Factor Info
Valproic Acid	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Valproic Acid results in decreased methylation of SLC31A1 gene		[80]
Regulation Mechanism			Transcription Factor Info
Vanadium	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Vanadium results in decreased expression of SLC31A1 mRNA		[13]
Regulation Mechanism			Transcription Factor Info
Y 27632	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Y 27632 results in decreased expression of SLC31A1 mRNA		[81]
Regulation Mechanism			Transcription Factor Info
Zidovudine	1 DT Activity Modulations Related to This Exogenous Factor	Click to Show/Hide the Full List
DT Modulation1	Zidovudine co-treated with Lamivudine results in increased expression of SLC31A1 mRNA		[72]
Regulation Mechanism			Transcription Factor Info

References
1	Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res. 2009 Jun 1;15(11):3881-8.
2	Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
3	Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck. 2011 Jul;33(7):959-68.
4	Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma cells by reducing intracellular cisplatin accumulation. Mol Pharmacol. 2011 Mar;79(3):608-17.
5	Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
6	Mechanistic basis for overcoming platinum resistance using copper chelating agents. Mol Cancer Ther. 2012 Nov;11(11):2483-94.
7	Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
8	Regulation of the high-affinity copper transporter (hCtr1) expression by cisplatin and heavy metals. J Biol Inorg Chem. 2014 Jan;19(1):17-27.
9	Uptake of compounds that selectively kill multidrug-resistant cells: the copper transporter SLC31A1 (CTR1) increases cellular accumulation of the thiosemicarbazone NSC73306. Mol Pharm. 2014 Aug 4;11(8):2692-702.
10	Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975.
11	Influence of estrogens on copper indicators: in vivo and in vitro studies. Biol Trace Elem Res. 2010 Jun;134(3):252-64.
12	Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci. 2010 Jul 14;30(28):9500-9.
13	Endothelial effects of emission source particles: acute toxic response gene expression profiles. Toxicol In Vitro. 2009 Feb;23(1):67-77.
14	Pleiotropic combinatorial transcriptomes of human breast cancer cells exposed to mixtures of dietary phytoestrogens. Food Chem Toxicol. 2009 Apr;47(4):787-95.
15	Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds. Toxicol Appl Pharmacol. 2009 Apr 1;236(1):85-96.
16	Identification of early target genes of aflatoxin B1 in human hepatocytes, inter-individual variability and comparison with other genotoxic compounds. Toxicol Appl Pharmacol. 2012 Jan 15;258(2):176-87.
17	Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
18	Effects of different sources of copper on Ctr1, ATP7A, ATP7B, MT and DMT1 protein and gene expression in Caco-2 cells. J Trace Elem Med Biol. 2014 Jul;28(3):344-50.
19	Copper signaling axis as a target for prostate cancer therapeutics. Cancer Res. 2014 Oct 15;74(20):5819-31.
20	New insights into BaP-induced toxicity: role of major metabolites in transcriptomics and contribution to hepatocarcinogenesis. Arch Toxicol. 2016 Jun;90(6):1449-58.
21	A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
22	A trichostatin A expression signature identified by TempO-Seq targeted whole transcriptome profiling. PLoS One. 2017 May 25;12(5):e0178302.
23	Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells. J Biol Chem. 2018 Feb 16;293(7):2422-2437.
24	Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
25	Integration of transcriptome analysis with pathophysiological endpoints to evaluate cigarette smoke toxicity in an in vitro human airway tissue model. Arch Toxicol. 2021 May;95(5):1739-1761.
26	CD34+ derived macrophage and dendritic cells display differential responses to paraquat. Toxicol In Vitro. 2021 Sep;75:105198.
27	Dose- and Time-Dependent Transcriptional Response of Ishikawa Cells Exposed to Genistein. Toxicol Sci. 2016 May;151(1):71-87.
28	NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells. Oncotarget. 2016 Jul 12;7(28):43337-43351.
29	Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297.
30	Identification and characterization of 3-iodothyronamine intracellular transport. Endocrinology. 2009 Apr;150(4):1991-9.
31	Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
32	Integration of transcriptomics, proteomics and metabolomics data to reveal the biological mechanisms of abrin injury in human lung epithelial cells. Toxicol Lett. 2019;312:1-10.
33	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
34	Aflatoxin B1 induces persistent epigenomic effects in primary human hepatocytes associated with hepatocellular carcinoma. Toxicology. 2016 Mar 28;350-352:31-9.
35	The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res. 2006;66(22):10944-52.
36	Using transcriptomic signatures to elucidate individual and mixture effects of inorganic arsenic and manganese in human placental trophoblast HTR-8/SVneo cells. Toxicol Sci. 2025;203(2):216-226.
37	Transcription factor Sp1 plays an important role in the regulation of copper homeostasis in mammalian cells. Mol Pharmacol. 2008 Sep;74(3):705-13.
38	Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017;8(1):1369-1391.
39	Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res. 2009;15(2):553-60.
40	Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models. J Ovarian Res. 2013;6(1):78.
41	Cellular glutathione plays a key role in copper uptake mediated by human copper transporter 1. Am J Physiol Cell Physiol. 2013;304(8):C768-79.
42	Cadmium acute exposure induces metabolic and transcriptomic perturbations in human mature adipocytes. Toxicology. 2022;470:153153.
43	Long non-coding RNAs as novel expression signatures modulate DNA damage and repair in cadmium toxicology. Sci Rep. 2015;5:15293.
44	Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther. 2004;3(12):1543-9.
45	Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1. J Biol Chem. 2003;278(11):9639-46.
46	Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin. Mol Pharmacol. 2009;76(4):843-53.
47	Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1. Mol Pharmacol. 2013;83(1):85-94.
48	EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer. PLoS One. 2015;10(4):e0125402.
49	Integrin aV modulates the cellular pharmacology of copper and cisplatin by regulating expression of the influx transporter CTR1. Oncoscience. 2014;1(3):185-195.
50	Role of transporter genes in cisplatin resistance. In Vivo. 2008;22(3):279-83.
51	Proapoptotic effect on normal and tumor intestinal cells of cytostatic drugs with enterohepatic organotropism. J Pharmacol Exp Ther. 2005;315(1):24-35.
52	The role of the methionines and histidines in the transmembrane domain of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Mol Pharmacol. 2010;78(3):333-9.
53	Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells. J Inorg Biochem. 2012;116:1-10.
54	The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 2009;296(3):F505-11.
55	Upregulated copper transporters in hypoxia-induced pulmonary hypertension. PLoS One. 2014;9(3):e90544.
56	Copper depletion inhibits CoCl2-induced aggressive phenotype of MCF-7 cells via downregulation of HIF-1 and inhibition of Snail/Twist-mediated epithelial-mesenchymal transition. Sci Rep. 2015;5:12410.
57	Specificity protein 1 (sp1) oscillation is involved in copper homeostasis maintenance by regulating human high-affinity copper transporter 1 expression. Mol Pharmacol. 2012 Mar;81(3):455-64.
58	Impaired copper and iron metabolism in blood cells and muscles of patients affected by copper deficiency myeloneuropathy. Neuropathol Appl Neurobiol. 2014;40(7):888-98.
59	Copper and lactational hormones influence the CTR1 copper transporter in PMC42-LA mammary epithelial cell culture models. J Nutr Biochem. 2014;25(4):377-87.
60	Identification of methionine-rich clusters that regulate copper-stimulated endocytosis of the human Ctr1 copper transporter. J Biol Chem. 2004;279(17):17428-33.
61	Intestinal regulation of copper homeostasis: a developmental perspective. Am J Clin Nutr. 2008;88(3):846S-50S.
62	A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo. Free Radic Biol Med. 2011 Jan 1;50(1):110-21.
63	Copper uptake by DMT1: a compensatory mechanism for CTR1 deficiency in human umbilical vein endothelial cells. Metallomics. 2015;7(8):1285-9.
64	A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells. Mol Pharmacol. 2013;83(6):1237-46.
65	Mutation analysis of copper transporter genes in patients with ethylmalonic encephalopathy, mitochondriopathies and copper deficiency phenotypes. J Inherit Metab Dis. 2003;26(1):55-66.
66	Functional analyses of copper transporter genes in the human liver cell line HepG2. Toxicol In Vitro. 2020;66:104856.
67	Effects of copper on the expression of metal transporters in human intestinal Caco-2 cells. FEBS Lett. 2002;527(1-3):239-44.
68	Characterization of mouse embryonic cells deficient in the ctr1 high affinity copper transporter. Identification of a Ctr1-independent copper transport system. J Biol Chem. 2002;277(43):40253-9.
69	Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
70	Genome-wide study of DNA methylation alterations in response to diazinon exposure in vitro. Environ Toxicol Pharmacol. 2012;34(3):959-68.
71	Association between Organophosphate Ester Exposure and Insulin Resistance with Glycometabolic Disorders among Older Chinese Adults 60-69 Years of Age: Evidence from the China BAPE Study. Environ Health Perspect. 2023;131(4):47009.
72	Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005;20(2):139-46.
73	Stem Cell Transcriptome Responses and Corresponding Biomarkers That Indicate the Transition from Adaptive Responses to Cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
74	Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol. 2006 Jul;29(1):225-35.
75	A CRISPR screen identifies a pathway required for paraquat-induced cell death. Nat Chem Biol. 2017;13(12):1274-1279.
76	Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy. Gynecol Oncol. 2011;122(2):361-5.
77	Overcoming platinum resistance through the use of a copper-lowering agent. Mol Cancer Ther. 2012;11(6):1221-5.
78	Copper deprivation enhances the chemosensitivity of pancreatic cancer to rapamycin by mTORC1/2 inhibition. Chem Biol Interact. 2023;382:110546.
79	High-Throughput Transcriptomics of Nontumorigenic Breast Cells Exposed to Environmentally Relevant Chemicals. Environ Health Perspect. 2024;132(4):47002.
80	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
81	Pharmacological inhibition of Rho-kinase (ROCK) signaling enhances cisplatin resistance in neuroblastoma cells. Int J Oncol. 2010;37(5):1297-305.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.

Detail Information of Exogenous Modulation

Visitor Map

Correspondence